Fair Value Calculator Fair Value Calculator
EN DE

RELICAB (RELICAB) Fair Value & Analysis

IN · Market cap ₹398M

R RELICAB RELICAB · BSE
Price₹39.38
Fair Value₹37.67
Upside-4.3%
Quality44/100
Watch RELICAB for free — get notified when fair value or trend changes. Watch for free
Evidence: Medium Range ₹27.00 – ₹47.09

Fair value as of: Jul 6, 2026

From 14 valuation models · updated today

Share price −13.4% over the past month.

Price vs Fair Value (12 months)

₹86.10 ₹32.14 Fair Value ₹37.67 Jul 2025 Jul 2026

12‑month range ₹32.14 – ₹86.10 · fair‑value band ₹27.00 – ₹47.09 · the ₹39.38 price screens above the ₹37.67 fair value. As of Jul 6, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

RELICAB (RELICAB) currently trades at ₹39.38, while our model-based Fair Value estimate is ₹37.67 — implying the stock looks roughly 4.3% overvalued today. We read business quality at 44/100 (below-average quality). Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, RELICAB generated revenue of ₹642M at a net margin of 3.0%. Revenue grew 63.2% year over year. It earns a return on equity of 13.1%. Net debt stands at ₹144M. Fundamentals as of Jul 6, 2026

Our scenario range runs from ₹27.00 (bear case) to ₹47.09 (bull case); at ₹39.38, the current price sits within that range. The share trades about 56% below its 52-week high and 30% above its 52-week low, currently below its 200-day average.

Key figures & financial health

Revenue (TTM) ₹642M
Revenue growth (YoY) +63.2%
Net margin 3.0%
Return on equity 13.1%
Free cash flow −₹20.0M FY2026
P/E ratio 21.2
More key figures
Operating margin 4.7%
EPS (TTM) ₹1.86
EPS growth (YoY) +142%
Net debt ₹144M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 6, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

RELICAB reported revenue of ₹642M in FY2026 versus ₹336M in FY2022, a compound +17.6%/yr. Reported net income was ₹19.0M in FY2026, compounding +71.2%/yr from FY2022.

Revenue +17.6%/yr
FY22 ₹336M
FY23 ₹346M
FY24 ₹378M
FY25 ₹398M
FY26 ₹642M
Net income +71.2%/yr
FY22 ₹2.2M
FY23 ₹14.5M
FY24 ₹15.4M
FY25 ₹17.1M
FY26 ₹19.0M

Is RELICAB fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "RELICAB Fair Value". https://www.fairvalue-calculator.com/stock/RELICAB

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is RELICAB (RELICAB) undervalued?
As of Jul 6, 2026, our model estimates a fair value of ₹37.67 versus a price of ₹39.38 — about −4% (overvalued). Model-based estimate, not financial advice.
What is the fair value of RELICAB?
Our model-based fair value for RELICAB is ₹37.67 (as of Jul 6, 2026), built from audited fundamentals. The current price is ₹39.38.
What is the quality score of RELICAB?
RELICAB has a Quality Score of 44/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of RELICAB (RELICAB)?
RELICAB reported trailing-twelve-month revenue of about ₹642M (latest available figure, as of Jul 6, 2026).
What is the net profit margin of RELICAB?
The net profit margin of RELICAB is about 3.0%, meaning it keeps roughly 3.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.